A suit had been filed against Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals in the United States District Court by UCB INC., UCS Pharma GmbH, Research Corporation Technologies Inc. and Harris FRC Corporation, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of US Patent. If Glenmark is successful in its challenge of the patent, it will garner 180-day exclusivity for its products.
Glenmark Generics had filed Abbreviated New Drug Applications (ANDAs) for Lacosamide Tablets, and Oral Solution with the US Food and Drug Administration (USFDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmark’s ANDA products are generic versions of VIPMAT.
According to IMS health data for the twelve months ending March 31, 2013, VIPMAT tablets and Solution had total US sales of approximately $353 million.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: